SHANGHAI, May 20, 2025 /PRNewswire/ — WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate market, today announced that the company received multiple top awards- “Best CEO”, “Best CFO”, “Best Company Board”, “Best IR Program”, “Best IR Professional”, and “Best ESG (Environmental, Social and Governance)” among different vote types, in the ranking of “2025 Asia (ex-Japan) Executive Team” by Extel (previously “Institutional Investor”).
This is the second year that WuXi XDC has participated in the Extel ranking and won multiple awards. With its outstanding comprehensive strength, WuXi XDC achieved the “Grand Slam” in all ranking categories and in three different sectors -“All market capitalization” , “Small and Medium-sized market capitalization”, and “Chinese mainland”.
As a leading international financial survey publisher, Extel creates its research-supported rankings and names award recipients based on combined buy-side and sell-side surveys within the industry. The ranking and award recipients have been seen as impactful to the capital market since its debut. This year, 5,437 investment professionals from 1,167 financial service firms casted votes in core areas including accessibility of senior executives, execution of strategy, well-informed and empowered IR Team, timeliness of disclosure, corporate and board governance, and ESG performance.
Mr. Michael Xi, CFO of WuXi XDC, stated, “As a leading global CRDMO, we have been honored with multiple awards in the Extel Award for two consecutive years. This accomplishment signifies the international capital market’s recognition of WuXi XDC’s strategic positioning, corporate governance and social returns, and value creation capabilities. This award serves as both recognition and a responsibility. WuXi XDC will continue to foster a rewarding cycle of business growth and shareholder returns by maintaining deep market insights into bioconjugate development and enhancing global operational efficiency”.
WuXi XDC was listed on the Hong Kong Stock Exchange Main Board in November 2023, raising over HKD 4 billion（post green-shoe）and was named “Best IPO” by IFR Asia that year. In March 2024, the company was included in the stock list of Hong Kong Stock Connect. As of Today, WuXi XDC has been officially covered by over 30 sell-side analysts/firms, including major domestic and global sell-side institutions and the holding percentage of Hong Kong Stock Connect in WuXi XDC’s total issued shares has climbed to over 13%. The company has been included as a component stock in multiple indices, such as the Hang Seng Composite Index (HSCI), the Hang Seng Hong Kong Listed Biotechnology Index (HSHKBIO), the Hang Seng Healthcare Index (HSHCI), the Hang Seng Hong Kong US Biotechnology Index (HSUSB), and the FTSE All-Cap, etc. In the realm of capital market accolades, the company has been the recipient of prestigious industry honors including “Top Investor-Picked Companies”, “Most Valuable Pharmaceutical and Healthcare Company”, “Most Promising Hong Kong-listed Pharma Company”, “A Rating in the Wind ESG Rankings” and “Top 20 Pharmaceutical Listed Companies in ESG Competitiveness 2024”.
In 2024, WuXi XDC has continued to reinforce its leading position in the ADC and bioconjugates CRDMO field, with revenue increased by 90.8% YoY to RMB 4,052 million, and net profit surged by 277.2% YoY to RMB 1,070 million. As of December 31, 2024, the company has cumulatively served nearly 500 global customers and successfully delivered over 14,000 bioconjugate molecules. The “Enable, Follow and Win the Molecule” strategy continued to drive sustained and rapid project growth. By the end of 2024, the total number of integrated CMC projects had reached 194, supporting 85 IND submissions. 13 out of top 20 global pharmaceutical companies have partnered with company for R&D and manufacturing services of ADCs and broader bioconjugates.
About WuXi XDC
WuXi XDC Cayman Inc. (“WuXi XDC” or the “Company”, stock code: 2268.HK) is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: www.wuxixdc.com.
WuXi XDC Contacts
Investor: [email protected]
Media: [email protected]
BD: [email protected]
